SK to target the KRW 1 trillion global market of sleep disorder treatments

SK Biopharmaceuticals announced on the 21st the company completed the NDA(New Drug Application) process to the U.S. FDA for SKL-N05(generic name: Solriamfetol) with U.S. Jazz Pharmaceuticals, the world’s leading company in the sleeping disorder market. 

Once the FDA approves it, it is expected to make collective royalties by its sales in the U.S. from the year of 2019 at the earliest, and have...